Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $46,730 | 2,705 | 56.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $22,147 | 55 | 26.9% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $8,000 | 7 | 9.7% |
| Travel and Lodging | $3,839 | 19 | 4.7% |
| Gift | $1,430 | 1 | 1.7% |
| Education | $230.74 | 11 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| LivaNova USA, Inc. | $15,795 | 39 | $0 (2024) |
| Acorda Therapeutics, Inc | $12,957 | 71 | $0 (2024) |
| US WorldMeds, LLC | $5,532 | 48 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $4,123 | 173 | $0 (2024) |
| UCB, Inc. | $3,677 | 257 | $0 (2024) |
| ABBVIE INC. | $2,582 | 192 | $0 (2024) |
| Biogen, Inc. | $2,223 | 163 | $0 (2024) |
| CSL Behring | $2,123 | 74 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $1,568 | 109 | $0 (2024) |
| Boston Scientific Corporation | $1,499 | 9 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,858 | 331 | ABBVIE INC. ($774.87) |
| 2023 | $11,266 | 354 | LivaNova USA, Inc. ($3,387) |
| 2022 | $7,869 | 386 | LivaNova USA, Inc. ($1,272) |
| 2021 | $11,302 | 402 | Acorda Therapeutics, Inc ($4,671) |
| 2020 | $12,623 | 314 | Acorda Therapeutics, Inc ($7,555) |
| 2019 | $10,120 | 392 | US WorldMeds, LLC ($2,833) |
| 2018 | $13,204 | 333 | LivaNova USA, Inc. ($6,249) |
| 2017 | $9,135 | 286 | LivaNova USA, Inc. ($2,782) |
All Payment Transactions
2,798 individual payment records from CMS Open Payments — Page 1 of 112
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $33.18 | General |
| Category: Immunology | ||||||
| 12/20/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Food and Beverage | In-kind items and services | $23.94 | General |
| Category: Musculoskeletal | ||||||
| 12/20/2024 | Biogen, Inc. | AVONEX (Biological), TYSABRI, VUMERITY | Food and Beverage | In-kind items and services | $22.40 | General |
| Category: Neurology | ||||||
| 12/19/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $33.34 | General |
| Category: Immunology | ||||||
| 12/19/2024 | Biogen, Inc. | SKYCLARYS (Drug) | Food and Beverage | In-kind items and services | $27.96 | General |
| Category: Neurology | ||||||
| 12/19/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Food and Beverage | In-kind items and services | $15.85 | General |
| Category: NEUROLOGY | ||||||
| 12/17/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $25.22 | General |
| Category: Neurology | ||||||
| 12/17/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $19.77 | General |
| 12/16/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/12/2024 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $21.32 | General |
| Category: Neuroscience | ||||||
| 12/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Food and Beverage | In-kind items and services | $19.15 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $6.91 | General |
| Category: Neurology | ||||||
| 12/09/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $28.79 | General |
| Category: Neurology | ||||||
| 12/08/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $32.49 | General |
| Category: Immunology | ||||||
| 12/06/2024 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $17.23 | General |
| Category: Immunology | ||||||
| 12/06/2024 | ABBVIE INC. | BOTOX (Biological), QULIPTA | Food and Beverage | In-kind items and services | $13.20 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/04/2024 | ABBVIE INC. | VYALEV (Drug) | Food and Beverage | In-kind items and services | $18.71 | General |
| Category: NEUROSCIENCE | ||||||
| 12/03/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $13.03 | General |
| Category: PAIN | ||||||
| 12/02/2024 | Cycle Pharmaceuticals Inc | Tascenso ODT (Drug) | Food and Beverage | In-kind items and services | $46.90 | General |
| Category: NEUROLOGY | ||||||
| 12/02/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Food and Beverage | In-kind items and services | $23.84 | General |
| Category: NEUROLOGY | ||||||
| 11/27/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $32.49 | General |
| Category: Immunology | ||||||
| 11/26/2024 | Biogen, Inc. | AVONEX (Biological), TYSABRI, VUMERITY | Food and Beverage | In-kind items and services | $14.41 | General |
| Category: Neurology | ||||||
| 11/26/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $1.20 | General |
| Category: Neurology | ||||||
| 11/25/2024 | CATALYST PHARMACEUTICALS, INC. | FYCOMPA (Drug) | Food and Beverage | Cash or cash equivalent | $21.28 | General |
| Category: NEUROLOGY | ||||||
| 11/25/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $12.41 | General |
| Category: Neurology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 1,706 | 25,942 | $625,324 | $346,054 |
| 2022 | 22 | 1,787 | 27,680 | $675,328 | $355,612 |
| 2021 | 24 | 1,712 | 26,828 | $655,470 | $342,530 |
| 2020 | 23 | 1,888 | 25,672 | $672,855 | $330,032 |
All Medicare Procedures & Services
93 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 171 | 1,347 | $132,466 | $80,554 | 60.8% |
| J0586 | Injection, abobotulinumtoxina, 5 units | Office | 2023 | 26 | 10,740 | $121,147 | $67,771 | 55.9% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 25 | 12,005 | $109,545 | $57,138 | 52.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 367 | 496 | $72,740 | $38,855 | 53.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 173 | 182 | $33,670 | $16,646 | 49.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 138 | 145 | $19,575 | $12,549 | 64.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 113 | 113 | $23,036 | $12,243 | 53.1% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 241 | 268 | $15,403 | $9,938 | 64.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 146 | 157 | $15,700 | $9,303 | 59.3% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 20 | 57 | $14,875 | $6,124 | 41.2% |
| 64644 | Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | Office | 2023 | 16 | 42 | $11,514 | $5,063 | 44.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 64 | 116 | $6,960 | $4,883 | 70.2% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2023 | 16 | 16 | $6,880 | $4,185 | 60.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 32 | 35 | $6,741 | $3,782 | 56.1% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Office | 2023 | 31 | 72 | $6,760 | $3,765 | 55.7% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2023 | 28 | 29 | $8,265 | $3,617 | 43.8% |
| 64616 | Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | Office | 2023 | 13 | 24 | $7,695 | $3,497 | 45.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 13 | 13 | $3,466 | $2,159 | 62.3% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 18 | 18 | $2,498 | $1,227 | 49.1% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Office | 2023 | 26 | 26 | $2,886 | $1,177 | 40.8% |
| 95983 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | Office | 2023 | 17 | 29 | $2,260 | $840.84 | 37.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 12 | 12 | $1,242 | $739.44 | 59.5% |
| J0586 | Injection, abobotulinumtoxina, 5 units | Office | 2022 | 29 | 12,200 | $139,718 | $71,761 | 51.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 156 | 1,243 | $124,300 | $67,734 | 54.5% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 23 | 12,165 | $121,650 | $57,728 | 47.5% |
About Dr. David Greer, MD
Dr. David Greer, MD is a Neurology healthcare provider based in Huntsville, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/04/2007. The National Provider Identifier (NPI) number assigned to this provider is 1013064815.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Greer, MD has received a total of $82,376 in payments from pharmaceutical and medical device companies, with $6,858 received in 2024. These payments were reported across 2,798 transactions from 95 companies. The most common payment nature is "Food and Beverage" ($46,730).
As a Medicare-enrolled provider, Greer has provided services to 7,093 Medicare beneficiaries, totaling 106,122 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 93 distinct procedure/service records.
Practice Information
- Specialty Neurology
- Location Huntsville, AL
- Active Since 01/04/2007
- Last Updated 01/17/2020
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1013064815
Products in Payments
- VNS Therapy (Device) $13,462
- INBRIJA (Drug) $12,812
- Xadago (Drug) $5,172
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR (Device) $3,402
- Briviact (Drug) $2,167
- GILENYA (Drug) $2,147
- Hizentra (Biological) $2,070
- TYSABRI (Biological) $1,501
- NUPLAZID (Drug) $1,321
- BOTOX (Biological) $1,189
- APTIOM (Drug) $1,115
- NURTEC ODT (Drug) $1,115
- Aimovig (Biological) $1,102
- KESIMPTA (Drug) $1,065
- NUEDEXTA (Drug) $993.59
- TROKENDI XR (Drug) $963.47
- GOCOVRI (Drug) $859.46
- INGREZZA (Drug) $801.61
- Fycompa (Drug) $796.26
- Gamunex-C (Biological) $786.95
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Huntsville
Dr. Harry Mcdaris, M.d, M.D
Neurology — Payments: $417,976
Dr. Anjaneyulu Alapati, M.d, M.D
Neurology — Payments: $170,441
Bhageeradh Mulpur, M.d, M.D
Neurology — Payments: $74,035
Dr. Scott Hitchcock, D.o, D.O
Neurology — Payments: $44,311
Dr. David White
Neurology — Payments: $38,237
Amit Arora, M.d, M.D
Neurology — Payments: $22,201